Gandhi, Monica

A multinational Delphi consensus to end the COVID-19 public health threat

Lazarus, J. V., Romero, D., Kopka, C. J., Karim, S. A., Abu-Raddad, L. J., Almeida, G., Baptista-Leite, R., Barocas, J. A., Barreto, M. L., Bar-Yam, Y., et al. (2022) · Nature

COVID-19 epidemiological studiesLegal, Health, Environmental and COVID-19 Challenges

Cited by 226

Deep Learning and Glaucoma Specialists

Phene, S., Dunn, R. C., Hammel, N., Liu, Y., Krause, J., Kitade, N., Schaekermann, M., Sayres, R., Wu, D. J., Bora, A., et al. (2019) · Ophthalmology

Retinal Imaging and AnalysisGlaucoma and retinal disorders

Cited by 186

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., et al. (2021) · Science Advances

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 130

Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine

Carrico, A. W., Neilands, T. B., Dilworth, S. E., Evans, J. L., Gόmez, W., Jain, J. P., Gandhi, M., Shoptaw, S., Horvath, K. J., Coffin, L., et al. (2019) · Journal of the International AIDS Society

HIV, Drug Use, Sexual RiskSubstance Abuse Treatment and Outcomes

Cited by 79

Predictors of treatment-emergent resistance to dolutegravir

McCluskey, S. M., & Gandhi, M. (2025) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 10